Cargando…

Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease

SIMPLE SUMMARY: In this cohort study of cirrhotic patients with non-alcoholic fatty liver disease, we found that fibrosis-4 score (FIB-4) was associated with incident hepatocellular carcinoma (HCC) over a median follow up of 6 years, independently from metabolic co-factors (obesity and type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armandi, Angelo, Caviglia, Gian Paolo, Abdulle, Amina, Rosso, Chiara, Gjini, Kamela, Castelnuovo, Gabriele, Guariglia, Marta, Perez Diaz del Campo, Nuria, D’Amato, Daphne, Ribaldone, Davide Giuseppe, Saracco, Giorgio Maria, Bugianesi, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046647/ https://www.ncbi.nlm.nih.gov/pubmed/36980543 http://dx.doi.org/10.3390/cancers15061659

Ejemplares similares

Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Castelnuovo, Gabriele, et al.
Publicado: (2023)

The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

Role of Circadian Clock on the Pathogenesis and Lifestyle Management in Non-Alcoholic Fatty Liver Disease
por: Perez-Diaz-del-Campo, Nuria, et al.
Publicado: (2022)

Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2022)

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals
por: Armandi, Angelo, et al.
Publicado: (2022)

Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
por: Perez-Diaz-del-Campo, Nuria, et al.
Publicado: (2023)

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review
por: Armandi, Angelo, et al.
Publicado: (2021)

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

Fecal and Circulating Biomarkers for the Non-Invasive Assessment of Intestinal Permeability
por: Perez-Diaz-del-Campo, Nuria, et al.
Publicado: (2023)

Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis
por: Rosso, Chiara, et al.
Publicado: (2022)

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2021)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
por: Olivero, Antonella, et al.
Publicado: (2022)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
por: Bretto, Elisabetta, et al.
Publicado: (2023)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis
por: Rivera‐Esteban, Jesús, et al.
Publicado: (2021)

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

SEER-based risk stratification system for patients with primary non-cirrhotic liver cancer
por: Cao, Runmin, et al.
Publicado: (2023)

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Special Issue “Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice”
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
por: Donati, Benedetta, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o8t1n4nnmoqd8jn0mo05tphfs5